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Introduction
The TEL/AML1 fusion gene is generated by t(12;21)(p13;q22), the most frequent chromosomal translocation in childhood acute lymphoblastic leukemia 1 . There is convincing evidence that the gene fusion already takes place in utero in the majority of children with TEL/AML1 positive ALL and this suggests, together with studies in twins, that it represents an early, or even initiating, event in leukemia development 2, 3 . This translocation, however, is not sufficient for the manifestation of a clinical disease, but seems rather to induce a protracted preleukemic state in which additional postnatal genetic events may accumulate, eventually leading to malignant transformation 4, 5 .
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The role of TEL/AML1 expression in the affected cell was recently addressed in several studies and indicates an interference with differentiation in the B-lineage as well as enhanced self-renewal of B cells [6] [7] [8] . Importantly, such mutations that impair hematopoietic differentiation are assumed to interfere also with apoptosis 9 . The mechanisms by which the fusion protein breaches this crucial anticancer shield have, so far, not been identified.
The function of genes, in particular of fusion genes, has been studied in recent years by gene silencing using RNA interference (RNAi), a powerful strategy to specifically target the gene of interest 10 . In this study, we investigated the functional contribution of TEL/AML1 to the malignant phenotype focusing on the evasion of programmed cell death by silencing the fusion gene in the t(12;21) positive cell line REH.
Study design
Cell culture. The B cell precursor (BCP) leukemic cell line REH (having the TEL/AML1 fusion gene, the second TEL allele deleted and AML1 retained) and the mouse IL3 dependent BCP Ba/F3 cells were grown in 24-well plates (Nunc, Roskilde, Denmark) at 1x10 6 cells/mL. 
Results and Discussion
Several siRNAs targeting the fusion site of the TEL/AML1 mRNA were tested ( Figure 1A ).
Based on their influence on the fusion gene expression C1 was chosen as the functional and S as the control siRNA and used in all further experiments. To obtain efficient silencing of TEL/AML1 in REH cells, siRNAs were transfected twice according to the time course depicted in Figure 1B and protein depletion was confirmed at day six of the experiment only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 5 ( Figure 1C ). At this time cell viability was largely unaffected. However, two days later, cultures that were devoid of the fusion protein had a reduction of the cell count by about 60%, while those treated with the control siRNA S were only reduced by 20% compared to untreated REH cells. Moreover, assessment of early and late apoptosis indicated that the majority of TEL/AML1 silenced cells had started the apoptotic program whereas controls contained only 10-15% mostly early apoptotic cells ( Figure 1D ). These data suggest that TEL/AML1 interferes with the delicate balance between life and death probably by engaging a potent anti-apoptotic mechanism.
Having demonstrated the impact of TEL/AML1 protein depletion on cell survival, we set out to unravel the corresponding molecular mechanism. We employed gene expression analysis in TEL/AML1 silenced cells and searched for affected genes that are involved in the control of cell survival and apoptosis. Interestingly, HSP90 and HSP70 were consistently found to be down-regulated after TEL/AML1 depletion in two independent experiments. The nonfunctional siRNA S was used as a control to prove that the results were obtained from specific silencing of the fusion gene. For this purpose the expression of interferon responsive genes 10 was evaluated and found not to differ between these two populations (data not shown). To further confirm our findings on the protein level, we used high-resolution 2D gel electrophoresis of cytoplasmic proteins that were either metabolically labeled or stained, allowing quantification of synthesis rate and the amount of individual proteins, respectively.
In TEL/AML1 silenced cells (day 6 of the experiment, Figure 1B ) the synthesis rate and quantity of HSP90 had decreased whereas HSP70 showed only a reduced synthesis rate (Figure 2A,B) . Strikingly, both proteins were reduced two days later ( Figure 2C ). Further scrutiny of our gene expression data revealed a differential regulation of survivin upon silencing, a finding that was substantiated by reduced amounts of survivin protein two days later ( Figure 2C ) and correlated well with the high rate of apoptosis in these cells. To further only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 6 corroborate the relationship between the fusion protein and HSP90 expression, TEL/AML1 was ectopically expressed in Ba/F3 cells, which was followed by up-regulation of HSP90 and survivin ( Figure 2D ). The suggested anti-apoptotic effect of TEL/AML1 was supported in this model system since Ba/F3 cells expressing the fusion gene were resistant against growth factor withdrawal as well as VP16 treatment ( Figure 2E ). Further studies need to clarify the mode by which TEL/AML1 influences HSP expression and in particular it's possible interference with heat shock factors, dominant regulators of HSP 13 .
In this study we present in two model systems a clear functional relationship between TEL/AML1 and the apoptotic network with a major impact on the members of the heat shock protein family HSP90 and HSP70 as well as on survivin, a potent member of the inhibitor of the apoptosis IAP family [14] [15] [16] . The occurrence of TEL/AML1 and its interference with the apoptosis control enables the affected cell to survive, thereby providing the opportunity to acquire further mutations and eventually turn into a fully malignant phenotype. The propensity of leukemic REH cells to undergo apoptosis after TEL/AML1 depletion provides further evidence that this survival advantage is also indispensable for maintaining the leukemic phenotype, a feature that is shared by other leukemia-associated fusion genes [17] [18] [19] .
And finally, our data i) provide the rational for the potential clinical use of inhibitors against HSP 90 or survivin that are frequently up-regulated during cancer development 14, 16 and currently undergoing phase I clinical trials also for pediatric patients with recurrent or refractory ALL 20, 21 , and ii) support a future siRNA-based therapy 22 in this subtype of leukemia. Such targeted treatment approaches would ideally affect all the fusion gene carrying cells, be it the chemotherapy sensitive bulk of leukemic cells, or, more importantly, also the leukemic stem cell as well as the preleukemic clone, the definite and proposed sources of relapses, respectively. [23] [24] [25] only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From On page 5533 of the June 15, 2008, issue, there is an error in reporting the confidence intervals related to the 11% incidence of acute 2-IV graft-versus-host disease. The first sentence of the second paragraph under the heading "Survival and toxicity" should have read: "The incidence of grade 2-IV acute GVHD was 11% (95% CI, 5%-24%; Figure 4 )." HeLa cells in 12-well plates were cotransfected with 0.3 g plasmids encoding either GFP or GFP-Nur77⌬DBD in combination with 1 g plasmids encoding the 6 antiapoptotic Bcl-2 family members. After 1 day, cells were washed with PBS, fixed with 3.7% formaldehyde, and stained with DAPI to visualize nuclei by UV microscopy. The percentages of apoptotic cells were determined by counting 200 GFP-positive cells, scoring cells having nuclear fragmentation and/or chromatin condensation. Data are reported as means plus or minus SE (n ϭ 3). For assessing protein expression (bottom 3 panels), lysates were prepared from transfected cells, normalized for total protein content, and analyzed by SDS-PAGE/immunoblotting using Bcl-2, Myc, and GFP antibodies. The Bcl-2 data were derived from a single blot, and the bands were aligned with the apoptosis results for clarity of presentation.
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